[Skip to Navigation]
Original Investigation
December 6, 2023

Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification

Author Affiliations
  • 1Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York
  • 2Department of Statistics and Data Science, Cornell University, New York, New York
  • 3Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut
  • 4Department of Epidemiology, University of Alabama at Birmingham, Birmingham
  • 5Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham
  • 6Division of Cardiology, UT Southwestern Medical Center, Dallas, Texas
  • 7Department of Population Health Sciences, Weill Cornell Medical College, Cornell University, New York, New York
JAMA Cardiol. 2024;9(1):55-62. doi:10.1001/jamacardio.2023.4520
Key Points

Question  Is the removal of race stratification from the atherosclerotic cardiovascular disease pooled cohort risk equations (PCEs) associated with a change model performance?

Findings  In this cohort study of 11 638 participants, removal of race-specific and race-stratified PCEs and the addition of social determinants of health (SDOH) did not change model performance or calibration compared with the original PCE.

Meaning  Results suggest that removal of race or the addition of SDOH did not improve model performance in any subgroup.

Abstract

Importance  Use of race-specific risk prediction in clinical medicine is being questioned. Yet, the most commonly used prediction tool for atherosclerotic cardiovascular disease (ASCVD)—pooled cohort risk equations (PCEs)—uses race stratification.

Objective  To quantify the incremental value of race-specific PCEs and determine whether adding social determinants of health (SDOH) instead of race improves model performance.

Design, Setting, and Participants  Included in this analysis were participants from the biracial Reasons for Geographic and Racial Differences in Stroke (REGARDS) prospective cohort study. Participants were aged 45 to 79 years, without ASCVD, and with low-density lipoprotein cholesterol level of 70 to 189 mg/dL or non–high-density lipoprotein cholesterol level of 100 to 219 mg/dL at baseline during the period of 2003 to 2007. Participants were followed up to 10 years for incident ASCVD, including myocardial infarction, coronary heart disease death, and fatal and nonfatal stroke. Study data were analyzed from July 2022 to February 2023.

Main outcome/measures  Discrimination (C statistic, Net Reclassification Index [NRI]), and calibration (plots, Nam D’Agostino test statistic comparing observed to predicted events) were assessed for the original PCE, then for a set of best-fit, race-stratified equations including the same variables as in the PCE (model C), best-fit equations without race stratification (model D), and best-fit equations without race stratification but including SDOH as covariates (model E).

Results  This study included 11 638 participants (mean [SD] age, 61.8 [8.3] years; 6764 female [58.1%]) from the REGARDS cohort. Across all strata (Black female, Black male, White female, and White male participants), C statistics did not change substantively compared with model C (Black female, 0.71; 95% CI, 0.68-0.75; Black male, 0.68; 95% CI, 0.64-0.73; White female, 0.77; 95% CI, 0.74-0.81; White male, 0.68; 95% CI, 0.64-0.71), in model D (Black female, 0.71; 95% CI, 0.67-0.75; Black male, 0.68; 95% CI, 0.63-0.72; White female, 0.76; 95% CI, 0.73-0.80; White male, 0.68; 95% CI, 0.65-0.71), or in model E (Black female, 0.72; 95% CI, 0.68-0.76; Black male, 0.68; 95% CI, 0.64-0.72; White female, 0.77; 95% CI, 0.74-0.80; White male, 0.68; 95% CI, 0.65-0.71). Comparing model D with E using the NRI showed a net percentage decline in the correct assignment to higher risk for male but not female individuals. The Nam D’Agostino test was not significant for all race-sex strata in each model series, indicating good calibration in all groups.

Conclusions  Results of this cohort study suggest that PCE performed well overall but had poorer performance in both BM and WM participants compared with female participants regardless of race in the REGARDS cohort. Removal of race or the addition of SDOH did not improve model performance in any subgroup.

Add or change institution
1 Comment for this article
What about adding inflammation (CRP) risk to cardiovascular risk calculations?
Wayne Kaesemeyer, MD | Augusta Hypertension PC
What about adding inflammation (CRP) risk to cardiovascular risk calculations, especially since inflammation risk is more predictive of MACE than LDL risk as seen in a recent meta-analysis of three large trials
(Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials. The Lancet. 2023. doi:10.1016/s0140-6736(23)00215-5 )
Currently the Reynolds risk score is the only risk calculator that incorporates CRP. But it not is commonly used. A risk calculator that incorporates CRP that is readily usable is needed.
CONFLICT OF INTEREST: None Reported
×